Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for ...

Shares of Novavax Inc. NVAX climbed 17.99% to $8.33 Friday, on what proved to be an all-around favorable trading session for ...

Bullish option flow detected in Novavax (NVAX) with 9,851 calls trading, 2x expected, and implied vol increasing over 1 point to 83.26%. Jan-26 ...

B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2024. Novavax, Inc. (Nasdaq: NVAX), a ...

Novavax Inc. closed 70.41% below its 52-week high of $23.86, which the company reached on June 6th.

Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a ...

Reports Q4 revenue $88.3M, consensus $84.38M. “In 2024, we unveiled our new corporate growth strategy, shifting our focus from commercializing ...